Selumetinib

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

NF type1 With Inoperable Plexiform Neurofibromas

Conditions

NF type1 With Inoperable Plexiform Neurofibromas

Trial Timeline

— → —

NCT ID

NCT03259633

About Selumetinib

Selumetinib is a pre-clinical stage product being developed by AstraZeneca for NF type1 With Inoperable Plexiform Neurofibromas. The current trial status is completed. This product is registered under clinical trial identifier NCT03259633. Target conditions include NF type1 With Inoperable Plexiform Neurofibromas.

What happened to similar drugs?

1 of 2 similar drugs in NF type1 With Inoperable Plexiform Neurofibromas were approved

Approved (1) Terminated (0) Active (1)

✅AspartNovo NordiskApproved

🔄verapamil 120mg tablet + placeboDexcomPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03259633	Pre-clinical	Completed	—	—	NF type1 With Inoperable Plexiform Neurofibromas
NCT04924608	Phase 3	Active	Nov 19, 2021	Feb 15, 2029	Neurofibromatosis 1
NCT05101148	Phase 1	Active	Jul 21, 2021	Apr 28, 2028	Neurofibromatosis Type 1
NCT04590235	Phase 1	Active	Dec 16, 2020	Aug 31, 2026	Neurofibromatosis 1
NCT04495127	Phase 1	Completed	Aug 31, 2020	Mar 24, 2023	Neurofibromatosis Type 1
NCT03326388	Phase 1/2	Completed	Sep 26, 2019	Feb 14, 2024	Neurofibromatosis Type 1
NCT03095248	Phase 2	Terminated	May 8, 2017	May 21, 2024	Neurofibromatosis 2
NCT02063204	Phase 1	Completed	Mar 1, 2014	Jul 1, 2014	Solid Tumours
NCT01960374	Phase 1	Completed	Oct 1, 2013	May 1, 2014	Healthy Volunteers Pharmacokinetic Study
NCT01752569	Phase 1/2	Terminated	Jun 15, 2012	Dec 20, 2017	AIDS-related Kaposi's Sarcoma

Competing Products

11 competing products in NF type1 With Inoperable Plexiform Neurofibromas

See all competitors

Product	Company	Stage	Hype Score
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose	Precigen	Phase 1/2	26
Insulin Lispro	Eli Lilly	Phase 1	29
LY900014 + Insulin Lispro	Eli Lilly	Phase 2	35
Dapagliflozin + Placebo Oral Tablet	AstraZeneca	Phase 1	29
Semaglutide Pen Injector + Placebo	Novo Nordisk	Phase 2	42
Aspart	Novo Nordisk	Approved	43
Insulin glargine new formulation HOE901	Sanofi	Phase 1	29
Insulin glulisine (U300) + Insulin glulisine + Insulin aspart + NPH insulin + Glucagon + Glucose + Heparin	Sanofi	Phase 1	29
verapamil 120mg tablet + placebo	Dexcom	Phase 3	37
UP421	Sana Biotechnology	Phase 1	30
XeriSol glucagon	Xeris Pharmaceuticals	Phase 1	23